Article Text
PDF
Abstract
Introduction/Background Patients with cervical cancer treatment experience a deterioration of sexual function, which negatively affects their quality of life. Prevention of sexual dysfunction is an essential pillar in improving the quality of life of these patients.
The aim of this trial is to assess the impact on sexual function and self-perceived quality of life by including prevention of vaginal dysfunction and patient education compared with standard practice.
Methodology Multi-institutional, national, randomized clinical trial where patients will be randomized 1:1 at diagnosis of cervical cancer to control arm or intervention arm. After treatment, control arm patients will undergo standard follow-up by their referring physician.
The multimodal intervention for patients in the intervention group will include:
Application of vaginal estrogens plus hyaluronic-acid cream along with the use of vaginal vibrator
Systematic evaluation of the need of systemic hormone replacement therapy and treatment if needed
Access to online content about sexuality, nutrition, sports and lifestyle habits
Through four appointments (baseline, 1, 6 and 12 months after treatment), sexual health, vaginal trophism and self-perceived quality of life will be assessed with validated questionnaires such as FSFI, VIH, EORTC QLQ-30 and Cx-24.
122 eligible patients aged 18 years or over with FIGO Stage I-III cervical cancer treated with surgery and/or radiotherapy will be included and randomized.
Results The estimated date for presenting results is May 2026.
Conclusion A systematic multimodal intervention with prevention of vaginal dysfunction of patients after treatment for cervical cancer will improve the sexual function and self-perceived quality of life.
Disclosures The authors of this abstract have no disclosures.
